Bausch Health Companies Inc. (NYSE:BHC) Given Consensus Rating of “Hold” by Analysts

Bausch Health Companies Inc. (NYSE:BHC) has earned a consensus rating of “Hold” from the seven brokerages that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, five have given a hold recommendation and one has given a buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $7.75.

Several analysts have commented on BHC shares. StockNews.com upgraded shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a report on Friday, October 25th. Royal Bank of Canada lifted their price target on Bausch Health Companies from $10.00 to $11.00 and gave the company a “sector perform” rating in a research report on Friday, November 1st. Finally, Evercore ISI upgraded Bausch Health Companies to a “hold” rating in a report on Tuesday, October 15th.

Institutional Trading of Bausch Health Companies

A number of institutional investors and hedge funds have recently bought and sold shares of BHC. Goldentree Asset Management LP increased its position in shares of Bausch Health Companies by 31.0% during the third quarter. Goldentree Asset Management LP now owns 29,395,745 shares of the company’s stock valued at $239,552,000 after acquiring an additional 6,958,717 shares in the last quarter. Bank of Montreal Can raised its stake in shares of Bausch Health Companies by 234.0% in the third quarter. Bank of Montreal Can now owns 3,833,179 shares of the company’s stock worth $31,598,000 after purchasing an additional 2,685,675 shares during the last quarter. Maple Rock Capital Partners Inc. bought a new position in shares of Bausch Health Companies during the third quarter valued at $16,850,000. SG Americas Securities LLC boosted its position in shares of Bausch Health Companies by 62.0% during the fourth quarter. SG Americas Securities LLC now owns 3,301,981 shares of the company’s stock valued at $26,614,000 after buying an additional 1,263,706 shares during the last quarter. Finally, Mackenzie Financial Corp increased its holdings in Bausch Health Companies by 111.0% in the 2nd quarter. Mackenzie Financial Corp now owns 2,381,888 shares of the company’s stock worth $16,612,000 after buying an additional 1,252,834 shares in the last quarter. 78.65% of the stock is currently owned by institutional investors.

Bausch Health Companies Price Performance

BHC opened at $7.73 on Thursday. The firm has a market capitalization of $2.79 billion, a price-to-earnings ratio of -16.09 and a beta of 0.69. Bausch Health Companies has a one year low of $3.96 and a one year high of $11.46. The business has a 50 day simple moving average of $7.86 and a two-hundred day simple moving average of $7.45.

Bausch Health Companies (NYSE:BHC) last announced its quarterly earnings results on Wednesday, October 30th. The company reported $1.12 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.10. The company had revenue of $2.51 billion during the quarter, compared to analyst estimates of $2.42 billion. Bausch Health Companies had a negative return on equity of 755.86% and a negative net margin of 1.88%. The firm’s revenue was up 12.2% on a year-over-year basis. During the same quarter last year, the firm posted $1.03 earnings per share. As a group, sell-side analysts expect that Bausch Health Companies will post 3.73 EPS for the current fiscal year.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.